Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burton, K.
Right arrow Articles by Calne, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burton, K.
Right arrow Articles by Calne, D. B.
NEUROLOGY 1985;35:1205
© 1985 American Academy of Neurology

Parkinson's disease

A comparison of mesulergine and bromocriptine

Keith Burton, T. Andreo Larsen, R. Gordon Robinson, Paul J. Bratty, W. R. Wayne Martin, Michael Schulzer and Donald B. Calne

Division of Neurology (Drs. Burton, Larsen, Robinson, Bratty, Martin, and Calne) and the Department of Statistics (Dr. Schulzer), University of British Columbia, Vancouver, British Columbia, Canada.

Previous studies with mesulergine (CU 32-085) demonstrated safety and efficacy in short-term observations of patients with Parkinson's disease. We compared mesulergine with bromocriptine in 20 patients with Parkinson's disease. Eighteen patients completed the randomized, double-blind, crossover study. Clinical assessments employed the UBC scale and "Mini-Mental State" examination; neurvphysiologic measurements were undertaken on wrist rigidity and speed and accuracy of hand movement, and toxicity screening tests were compared. There were no significant differences between the effects of mesulergine (mean dosage, 27. 4 mg/d) and bromocriptine (mean dosage, 40. 8 mg/d).

Address correspondence and reprint requests to Dr. Calne, University of British Columbia, Head, Division of Neurology, 2211 Wesbrook Mall, Vancouver, B. C., Canada V6T 1WS.

Supported by the Dystonia Medical Research Foundation and the Medical Research Council of Canada.

Presented in part at the thirty-sixth annual meeting of the American Academy of Neurology, Roston, MA, April 1984.

Accepted for publication December 5, 1984.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.